Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence

Human Pathology

Volumn 44, Issue 9, 2013, Pages 1789-1796

  Tsourlakis, Maria Christina ^a   Schoop, Michael ^a   Plass, Christoph ^b   Huland, Hartwig ^a   Graefen, Markus ^a   Steuber, Thomas ^a   Schlomm, Thorsten ^a   Simon, Ronald ^a   Sauter, Guido ^a   Sirma, Hüseyin ^a   Minner, Sarah ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

DAXX; Prostate cancer; TMPRSS2 ERG

Indexed keywords

DEATH DOMAIN ASSOCIATED PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEINASE; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AVIAN ERYTHROBLASTOSIS ONCOVIRUS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE OVEREXPRESSION; GENE REARRANGEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROSTATE CANCER; TISSUE MICROARRAY;

DAXX; PROSTATE CANCER; TMPRSS2/ERG;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; AGED; CELL NUCLEUS; CELL PROLIFERATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883445987     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.01.022     Document Type: Article

References (35)

1. M. Graefen, S. Ahyai, and R. Heuer Active surveillance for prostate cancer Der Urologe Ausg A 47 2008 261 269
2. E.K. Markert, H. Mizuno, and A. Vazquez Molecular classification of prostate cancer using curated expression signatures Proc Natl Acad Sci U S A 108 2011 21276 21281
3. P. Peltomaki Mutations and epimutations in the origin of cancer Exp Cell Res 318 2012 299 310
4. M.F. Berger, M.S. Lawrence, and F. Demichelis The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
5. Y. Gui, G. Guo, and Y. Huang Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder Nat Genet 43 2011 875 878
6. J. Schwartzentruber, A. Korshunov, and X.Y. Liu Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 482 2012 226 231
7. Y. Jiao, C. Shi, and B.H. Edil DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
8. C.M. Heaphy, R.F. de Wilde, and Y. Jiao Altered telomeres in tumors with ATRX and DAXX mutations Science 333 2011 425
9. D.Y. Lin, H.I. Fang, and A.H. Ma Negative modulation of androgen receptor transcriptional activity by Daxx Mol Cell Biol 24 2004 10529 10541
10. S. Minner, M. Enodien, and H. Sirma ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin Cancer Res 17 2011 5878 5888
11. S. Minner, B. Jessen, and L. Stiedenroth Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer Clin Cancer Res 16 2010 1553 1560
12. T. Schlomm, L. Iwers, and P. Kirstein Clinical significance of p53 alterations in surgically treated prostate cancers Mod Pathol 21 2008 1371 1379
13. A. Krohn, T. Diedler, and L. Burkhardt Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer Am J Pathol 181 2012 401 412
14. P. Tennstedt, P. Koster, and A. Bruchmann The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers Int J Oncol 40 2012 261 268
15. A.T. El Gammal, M. Bruchmann, and J. Zustin Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer Clin Cancer Res 16 2010 56 64
16. T. Schlomm, P. Kirstein, and L. Iwers Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer Clin Cancer Res 13 2007 6579 6584
17. J. Kollermann, T. Schlomm, and H. Bang Expression and prognostic relevance of annexin A3 in prostate cancer Eur Urol 54 2008 1314 1323
18. J. Muller, A. Ehlers, and L. Burkhardt Loss of p(Ser2448)-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers Int J Cancer 132 2013 1333 1340
19. S.L. Tzeng, Y.W. Cheng, and C.H. Li Physiological and functional interactions between Tcf4 and Daxx in colon cancer cells J Biol Chem 281 2006 15405 15411
20. C.R. Lindsay, V.M. Morozov, and A.M. Ishov PML NBs (ND10) and Daxx: from nuclear structure to protein function Front Biosci 13 2008 7132 7142
21. T. Misteli Higher-order genome organization in human disease Cold Spring Harb Perspect Biol 2 2010 a000794
22. V.R. Iyer Nucleosome positioning: bringing order to the eukaryotic genome Trends Cell Biol 22 2012 250 256
23. J. Tang, L.K. Qu, and J. Zhang Critical role for Daxx in regulating Mdm2 Nat Cell Biol 8 2006 855 862
24. S. Yachida, E. Vakiani, and C.M. White Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors Am J Surg Pathol 36 2012 173 184
25. H.F. Yuen, Y.P. Chan, and S. Law DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma Cancer Epidemiol Biomarkers Prev 17 2008 3593 3602
26. K. Neben, A. Korshunov, and A. Benner Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival Cancer Res 64 2004 3103 3111
27. J. Yu, R.S. Mani, and Q. Cao An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression Cancer Cell 17 2010 443 454
28. J.C. Brase, M. Johannes, and H. Mannsperger TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling BMC Cancer 11 2011 507
29. P. Drane, K. Ouararhni, and A. Depaux The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3 Genes Dev 24 2010 1253 1265
30. P.W. Lewis, S.J. Elsaesser, and K.M. Noh Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres Proc Natl Acad Sci U S A 107 2010 14075 14080
31. Y. Chen, and C.L. Sawyers Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers Cancer Cell 17 2010 415 416
32. S.A. Tomlins, B. Laxman, and S. Varambally Role of the TMPRSS2-ERG gene fusion in prostate cancer Neoplasia 10 2008 177 188
33. C. Sun, A. Dobi, and A. Mohamed TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation Oncogene 27 2008 5348 5353
34. R. Li, H. Pei, and D.K. Watson EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes Oncogene 19 2000 745 753
35. Y. Murakami, S. Yamagoe, and K. Noguchi Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx J Biol Chem 281 2006 28113 28121